SCHEMBL7469077

SCHEMBL7469077

CCCCNCC(C)(C)C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 3/20 0.44
ADH1A P07327 3/20 0.44
ADH7 P40394 3/20 0.44
ADH1C P00326 2/20 0.44
TSHR P16473 3/20 0.44
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 1/20 0.40
EPHX1 P07099 3/20 0.38
ADH4 P08319 1/20 0.38
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA14 Q9ULX7 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9935804 0.91 EPHX1 (0.50) ADH1BADH1AADH7ADH1CTSHR
SCHEMBL9936340 0.91 EPHX1 (0.50) ADH1BADH1AADH7ADH1CTSHR
SCHEMBL2241713 0.80 PTGS1 (0.35)
SCHEMBL9936326 0.75
SCHEMBL10198685 0.75 TSHR (0.52) ADH1BADH1AADH7ADH1CTSHR
SCHEMBL23136900 0.75 KDM4E (0.35) TSHRSMN1; SMN2ALDH1A1GAA
SCHEMBL4075807 0.75 ADRA1A (0.37) TSHRALDH1A1HDAC3HDAC1HDAC2
SCHEMBL13937213 0.71 TSHR (0.48) ADH1BADH1AADH7ADH1CTSHR
SCHEMBL21553357 0.71 TSHR (0.48) ADH1BADH1AADH7ADH1CTSHR
SCHEMBL15114076 0.71 TSHR (0.48) ADH1BADH1AADH7ADH1CTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651876-B1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-09 EP claimed
US-8877955-B2 Secondary aminosilanes SIKA TECHNOLOGY AG (CH) 2014-11-04 US claimed
US-20130281562-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2013-10-24 US claimed
EP-2651876-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130261270-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-10-03 US claimed
EP-2468759-A1 Secondary Aminosilanes Sika Technology AG (CH) 2012-06-27 EP claimed
WO-2012080265-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465843-A1 Polyamines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
EP-3484898-B1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE MOMENTIVE PERFORMANCE MAT INC (US) 2023-06-28 EP disclosed
EP-4053134-A1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE Momentive Performance Materials Inc. (US) 2022-09-07 EP disclosed
CN-109563111-B Method for stabilizing imino-functional silanes 莫门蒂夫性能材料股份有限公司 2022-04-12 CN disclosed
US-11230563-B2 Method of stabilizing imino-functional silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2022-01-25 US disclosed
EP-3350157-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX INC (US) 2022-01-05 EP disclosed
US-10457697-B2 Method of stabilizing imino-functional silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2019-10-29 US disclosed
US-6136826-A AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2000-10-24 US disclosed
CN-1052224-C Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients OTSUKA PHARMA CO LTD (JP) 2000-05-10 CN disclosed
US-5760058-A Peripheral vasodilating agent containing piperidine derivative as active ingredient OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-06-02 US disclosed
US-5656642-A Peripheral vasodilating agent containing piperidine derivative as active ingredient OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US disclosed
EP-0650476-A1 PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-05-03 EP disclosed
WO-1994022826-A1 PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230563-B2 Method of stabilizing imino-functional silane INF2, RNF168, BOLA2; BOLA2B ADH1B 3143/4885ADH1A 1807/4885ADH7 2196/4885
US-20130281562-A1 SECONDARY AMINOSILANES AS3MT, SRM, MSN ADH1B 4383/4885ADH1A 3967/4885ADH7 4282/4885
US-10457697-B2 Method of stabilizing imino-functional silane INF2, RNF168, BOLA2; BOLA2B ADH1B 3143/4885ADH1A 1807/4885ADH7 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.